[1]
Olden KW,Chey WD,Shringarpure R,Paul Nicandro J,Chuang E,Earnest DL, Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current medical research and opinion. 2019 Mar;
[PubMed PMID: 30293448]
Level 2 (mid-level) evidence
[2]
Miller JL, Alosetron approved for treatment of irritable bowel syndrome. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2000 Mar 15;
[PubMed PMID: 10754758]
[3]
Chang L,Chey WD,Harris L,Olden K,Surawicz C,Schoenfeld P, Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. The American journal of gastroenterology. 2006 May;
[PubMed PMID: 16606352]
Level 1 (high-level) evidence
[5]
Lewis JH, Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert review of gastroenterology
[PubMed PMID: 20136586]
Level 3 (low-level) evidence
[6]
Nee J,Zakari M,Lembo AJ, Novel Therapies in IBS-D Treatment. Current treatment options in gastroenterology. 2015 Dec;
[PubMed PMID: 26432092]
[7]
Lembo A,Ameen VZ,Drossman DA, Irritable bowel syndrome: toward an understanding of severity. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2005 Aug;
[PubMed PMID: 16233998]
Level 3 (low-level) evidence
[8]
Chen L,Ilham SJ,Feng B, Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article. Anesthesiology and pain medicine. 2017 Apr;
[PubMed PMID: 28824858]
[9]
Gershon MD, Serotonin and its implication for the management of irritable bowel syndrome. Reviews in gastroenterological disorders. 2003;
[PubMed PMID: 12776000]
[10]
Mayer EA,Berman S,Derbyshire SW,Suyenobu B,Chang L,Fitzgerald L,Mandelkern M,Hamm L,Vogt B,Naliboff BD, The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Alimentary pharmacology
[PubMed PMID: 12144587]
[11]
Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Advances in therapy. 2020 Jan:37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9
[PubMed PMID: 31707713]
Level 3 (low-level) evidence
[12]
Cangemi DJ,Lacy BE, Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Therapeutic advances in gastroenterology. 2019;
[PubMed PMID: 31632456]
Level 3 (low-level) evidence
[13]
Krause R,Ameen V,Gordon SH,West M,Heath AT,Perschy T,Carter EG, A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. The American journal of gastroenterology. 2007 Aug;
[PubMed PMID: 17509028]
Level 1 (high-level) evidence
[15]
Lacy BE, Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology
[PubMed PMID: 30194692]
[16]
Lucak SL, Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therapeutic advances in gastroenterology. 2010 May;
[PubMed PMID: 21180598]
Level 3 (low-level) evidence
[17]
Haus U,Späth M,Färber L, Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scandinavian journal of rheumatology. Supplement. 2004
[PubMed PMID: 15515406]
[18]
Tong K,Nicandro JP,Shringarpure R,Chuang E,Chang L, A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therapeutic advances in gastroenterology. 2013 Sep
[PubMed PMID: 24003335]
Level 3 (low-level) evidence
[19]
Martin GR, Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacology & therapeutics. 1994
[PubMed PMID: 7972337]
[20]
Potenza MA,Serio M,Montagnani M,Mansi G,Rinaldi R,Genualdo M,Mitolo-Chieppa D, Functional evaluation of 5-hydroxytryptamine receptor activity in rat resistance vessels. Journal of autonomic pharmacology. 1998 Apr
[PubMed PMID: 9730261]
[21]
Oral immunization of ducklings with attenuated duck hepatitis virus., Hanson LE,Tripathy DN,, Developments in biological standardization, 1976
[PubMed PMID: 11224663]
[22]
Cappell MS, Colonic toxicity of administered drugs and chemicals. The American journal of gastroenterology. 2004 Jun;
[PubMed PMID: 15180742]
[23]
Mayer EA,Bradesi S, Alosetron and irritable bowel syndrome. Expert opinion on pharmacotherapy. 2003 Nov;
[PubMed PMID: 14596662]
Level 3 (low-level) evidence